Log In
BCIQ
Print this Print this
 

ATI-9242

  Manage Alerts
Collapse Summary General Information
Company Cascadian Therapeutics Inc.
DescriptionNext-generation atypical antipsychotic agent modeled on clozapine
Molecular Target Dopamine D2 receptor ; Serotonin (5-HT) receptor
Mechanism of ActionSerotonin (5-HT1A) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat negative symptoms of schizophrenia
Regulatory Designation
PartnerBraeburn Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today